Preclinical and Clinical Characterization of the Selective 5-HT1Areceptor Antagonist DU-125530 for Antidepressant Treatment

British Journal of Pharmacology - United States
doi 10.1111/j.1476-5381.2011.01770.x
Full Text
Abstract

Available in full text

Categories
Pharmacology
Date
Authors
Publisher

Wiley

Related search

Preclinical Sex Differences in Depression and Antidepressant Response: Implications for Clinical Research

Journal of Neuroscience Research
Molecular NeuroscienceCellular
2016English

Treatment of Hypertension With Ketanserin, a New Selective 5-Ht2 Receptor Antagonist.

BMJ
1982English

5-Ht2b Receptors Are Required for Serotonin-Selective Antidepressant Actions

Molecular Psychiatry
PsychiatryMolecular NeuroscienceMental HealthMolecular BiologyCellular
2011English

Antidepressant and Anxiolytic Effects of Selective 5-Ht6 Receptor Agonists in Rats

Psychopharmacology
Pharmacology
2010English

Clinical Importance of Long-Term Antidepressant Treatment

British Journal of Psychiatry
MedicinePsychiatryMental Health
2001English

The Preclinical and Clinical Effects of Vilazodone for the Treatment of Major Depressive Disorder

Expert Opinion on Drug Discovery
Drug Discovery
2016English

Selective Activation of Postsynaptic 5-Ht1a Receptors Induces Rapid Antidepressant Response

Neuropsychopharmacology
PsychiatryMental HealthPharmacology
1997English

AE9C90CB: A Novel, Bladder-Selective Muscarinic Receptor Antagonist for the Treatment of Overactive Bladder

British Journal of Pharmacology
Pharmacology
2010English

Screening of 5-HT1AReceptor Antagonists Using Molecularly Imprinted Polymers

Journal of the American Chemical Society
BiochemistryColloidCatalysisChemistrySurface Chemistry
2007English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy